Blood-Based Biomarkers for Alzheimer's and Parkinson's Disease – Part B
- 1st Edition, Volume 193 - April 1, 2027
- Latest edition
- Editor: Subashchandrabose Chinnathambi
- Language: English
Blood-Based Biomarkers for Alzheimer's and Parkinson's Disease – Part B, published as Volume 193 of the serial International Review of Neurobiology, provides a comprehensiv… Read more
End of Summer Sale
Save up to 30% off
Bright savings for research, study, and discovery
Description
Description
Blood-Based Biomarkers for Alzheimer's and Parkinson's Disease – Part B, published as Volume 193 of the serial International Review of Neurobiology, provides a comprehensive examination of emerging blood-based biomarkers and related biological mechanisms relevant to Alzheimer's disease, Parkinson's disease, vascular cognitive impairment, stroke, and other neuropsychiatric disorders. The volume highlights advances in biomarker discovery, genetic and epigenetic determinants of neurodegeneration, extracellular vesicles and exosomes, protein misfolding, microRNA dysregulation, blood-brain barrier dysfunction, and biofluid-based biosensing technologies. It also explores the integration of artificial intelligence with multimodal biomarker datasets to improve diagnosis, prognosis, and precision medicine approaches. Bringing together contributions from international experts, this volume offers researchers and clinicians an up-to-date resource on translational developments that are shaping the future of neurodegenerative disease detection and management.
Key features
Key features
- Reviews current advances in blood-based biomarkers for Alzheimer's disease and Parkinson's disease
- Examines genetic, epigenetic, and molecular mechanisms underlying neurodegeneration
- Highlights emerging biomarker platforms, including extracellular vesicles, exosomes, non-coding RNAs, and biofluid-based biosensors
- Explores the roles of protein misfolding, metal homeostasis, autophagy, and blood-brain barrier dysfunction in disease pathogenesis
- Discusses artificial intelligence and multimodal biomarker integration for precision diagnosis and prognosis
- Provides authoritative perspectives from leading researchers across neurobiology, neurology, and translational neuroscience
Readership
Readership
Neuroscientists and neurobiologists; Neurologists and clinician-scientists; Alzheimer's disease and Parkinson's disease researchers; Biomarker and translational medicine investigators; Molecular neuroscience and neurogenetics researchers; Clinical pathology and laboratory diagnostics professionals; Neuroinformatics and artificial intelligence researchers; Graduate students and advanced trainees in neuroscience and neurology
Table of contents
Table of contents
1. Blood-based Biomarkers and Their Role in PD Diagnosis
2. Progress in Blood-Derived Biomarkers for Parkinson's Disease
3. Small Non-Coding RNAs and Dopaminergic Dysfunction: Emerging Biomarkers
4. Cognitive Load in Neurodegeneration: Predictive Processing, Dopaminergic Modulation, and AI Modeling for Mitigating Decline
5. Genetic and Epigenetic Complexity of Parkinson's Disease
6. Blood Based Biomarkers in Vascular Cognitive Impairment
7. Protein Misfolding and microRNA Dysregulation in Parkinson's Disease: Convergent Pathogenic Axes
8. Blood-based Biomarkers for Parkinson's Disease Towards the Biological Definition
9. Biofluid-Based Biosensors
10. Disruption of Zinc Homeostasis and Its Role in Neurodegenerative Diseases
11. Blood-Brain Barrier Breakdown in Ischemic Stroke: Mechanisms, Biomarkers, and Therapeutic Targets
12. From Neurons to Glial Cells: The Overlooked Mechanisms of Schizophrenia
13. Targeting Amyloid and Tau: Antibody Therapies for Alzheimer's Disease
14. Effect of Dietary Pattern on Biomarkers in Alzheimer's Disease
15. Endolysosomal Pathways and Autophagy Dysregulation in Alzheimer's Disease
16. Extracellular Vesicles in Alzheimer's and Parkinson's Disease
17. Advances in Alzheimer's Disease: Blood-Based Biomarkers for Early Detection and Precision Medicine
18. Exosomal Biomarkers for Alzheimer's Disease
19. Multi-modal Blood Biomarker Panels Combined with Artificial Intelligence: Toward Precision Diagnosis and Prognosis of Alzheimer's and Parkinson's Disease
2. Progress in Blood-Derived Biomarkers for Parkinson's Disease
3. Small Non-Coding RNAs and Dopaminergic Dysfunction: Emerging Biomarkers
4. Cognitive Load in Neurodegeneration: Predictive Processing, Dopaminergic Modulation, and AI Modeling for Mitigating Decline
5. Genetic and Epigenetic Complexity of Parkinson's Disease
6. Blood Based Biomarkers in Vascular Cognitive Impairment
7. Protein Misfolding and microRNA Dysregulation in Parkinson's Disease: Convergent Pathogenic Axes
8. Blood-based Biomarkers for Parkinson's Disease Towards the Biological Definition
9. Biofluid-Based Biosensors
10. Disruption of Zinc Homeostasis and Its Role in Neurodegenerative Diseases
11. Blood-Brain Barrier Breakdown in Ischemic Stroke: Mechanisms, Biomarkers, and Therapeutic Targets
12. From Neurons to Glial Cells: The Overlooked Mechanisms of Schizophrenia
13. Targeting Amyloid and Tau: Antibody Therapies for Alzheimer's Disease
14. Effect of Dietary Pattern on Biomarkers in Alzheimer's Disease
15. Endolysosomal Pathways and Autophagy Dysregulation in Alzheimer's Disease
16. Extracellular Vesicles in Alzheimer's and Parkinson's Disease
17. Advances in Alzheimer's Disease: Blood-Based Biomarkers for Early Detection and Precision Medicine
18. Exosomal Biomarkers for Alzheimer's Disease
19. Multi-modal Blood Biomarker Panels Combined with Artificial Intelligence: Toward Precision Diagnosis and Prognosis of Alzheimer's and Parkinson's Disease
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 193
- Published: April 1, 2027
- Language: English
About the editor
About the editor
SC
Subashchandrabose Chinnathambi
Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.
Affiliations and expertise
Additional Professor, Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India